keyword
MENU ▼
Read by QxMD icon Read
search

Aflibercept

keyword
https://www.readbyqxmd.com/read/29785301/impact-of-baseline-central-retinal-thickness-on-outcomes-in-the-vivid-dme-and-vista-dme-studies
#1
Edoardo Midena, Mark Gillies, Todd A Katz, Carola Metzig, Chengxing Lu, Yuichiro Ogura
Purpose: To report the impact of baseline central retinal thickness (CRT) on outcomes in patients with diabetic macular edema (DME) in VIVID-DME and VISTA-DME. Methods: Post hoc analyses of two randomized controlled trials in which 862 DME patients were randomized 1 : 1 : 1 to treatment with intravitreal aflibercept 2.0 mg every 4 weeks (2q4), intravitreal aflibercept 2.0 mg every 8 weeks after five initial monthly doses (2q8), or macular laser photocoagulation at baseline and as needed...
2018: Journal of Ophthalmology
https://www.readbyqxmd.com/read/29772018/the-cost-effectiveness-of-bevacizumab-ranibizumab-and-aflibercept-for-the-treatment-of-age-related-macular-degeneration-a-cost-effectiveness-analysis-from-a-societal-perspective
#2
Freekje van Asten, Charlotte T J Michels, Carel B Hoyng, Gert Jan van der Wilt, B Jeroen Klevering, Maroeska M Rovers, Janneke P C Grutters
BACKGROUND: The discussion on the use of bevacizumab is still ongoing and often doctors are deterred from using bevacizumab due to legal or political issues. Bevacizumab is an effective, safe and inexpensive treatment option for neovascular age-related macular degeneration (AMD), albeit unregistered for the disease. Therefore, in some countries ophthalmologists use the equally effective but expensive drugs ranibizumab and aflibercept. We describe the economic consequences of this dilemma surrounding AMD treatment from a societal perspective...
2018: PloS One
https://www.readbyqxmd.com/read/29771880/-anti-vegf-therapy-for-diabetic-macular-edema-from-theory-to-clinical-practice
#3
A Zh Fursova, N V Chubar, M S Tarasov, I F Niculich, M A Vasilyeva, O G Gusarevich
PURPOSE: To evaluate clinical effectiveness of aflibercept therapy for patients with diabetic macular edema (DME) - both naïve to the drug and unresponsive to previous anti-VEGF treatment. MATERIAL AND METHODS: The study included 127 patients (127 eyes) divided into two groups. The first group consisted of 100 primary DME patients (100 eyes) with mean age of 68.48±2.56 years and average disease duration of 12.50±7.85 years. The second group comprised 27 patients (27 eyes) with resistant macular edema who had received three or more 0...
2018: Vestnik Oftalmologii
https://www.readbyqxmd.com/read/29765959/outcome-of-5-year-treatment-of-neovascular-age-related-macular-degeneration-with-intravitreal-anti-vegf-using-treat-and-extend-regimen
#4
Polona Jaki Mekjavic, Polona Zaletel Benda
Objective: The aim of this study is twofold. First , to evaluate the long-term outcome of anti-vascular endothelial growth factor (anti-VEGF) treatment in a clinical setting using the "treat-and-extend regimen" (TER) in patients with neovascular age-related macular degeneration (nAMD). Second , to determine the proportion of patients treated with anti-VEGF with good visual acuity (VA), i.e., vision sufficient to maintain a high level of independence. Design: We conducted a single center retrospective review of patients with treatment-naive nAMD who were treated with anti-VEGF...
2018: Frontiers in Medicine
https://www.readbyqxmd.com/read/29748595/crispr-lbcpf1-prevents-choroidal-neovascularization-in-a-mouse-model-of-age-related-macular-degeneration
#5
Taeyoung Koo, Sung Wook Park, Dong Hyun Jo, Daesik Kim, Jin Hyoung Kim, Hee-Yeon Cho, Jeungeun Kim, Jeong Hun Kim, Jin-Soo Kim
LbCpf1, derived from Lachnospiraceae bacterium ND2006, is a CRISPR RNA-guided endonuclease and holds promise for therapeutic applications. Here we show that LbCpf1 can be used for therapeutic gene editing in a mouse model of age-related macular degeneration (AMD). The intravitreal delivery of LbCpf1, targeted to two angiogenesis-associated genes encoding vascular endothelial growth factor A (Vegfa) and hypoxia inducing factor 1a (Hif1a), using adeno-associated virus, led to efficient gene disruption with no apparent off-target effects in the retina and retinal pigment epithelium (RPE) cells...
May 10, 2018: Nature Communications
https://www.readbyqxmd.com/read/29746511/choroidal-structure-as-a-biomarker-for-visual-acuity-in-intravitreal-aflibercept-therapy-for-polypoidal-choroidal-vasculopathy
#6
Shotaro Asano, Keiko Azuma, Kimiko Shimizu, Risako Yamamoto, Jinhee Lee, Hiroshi Murata, Tatsuya Inoue, Ryo Asaoka, Ryo Obata
PURPOSE: To investigate the relationship between choroidal structure and visual acuity after intravitreal aflibercept therapy for polypoidal choroidal vasculopathy (PCV). METHODS: We conducted a retrospective, single-centre and observational study including 18 eyes of 18 patients with PCV (73.8 ± 10.2 years of age) who were treated with three monthly intravitreal aflibercept injections followed by additional treatments in a treat-and-extend protocol. The cross-sectional images of the macula were obtained with enhanced depth imaging optical coherence tomography at baseline, at 3 months, and at 12 months...
2018: PloS One
https://www.readbyqxmd.com/read/29743587/three-dimensional-tubule-formation-assay-as-therapeutic-screening-model-for-ocular-microvascular-disorders
#7
Mahnaz Shariatzadeh, Maarten M Brandt, Caroline Cheng, Josianne C Ten Berge, Aniki Rothova, Pieter J M Leenen, Willem A Dik
PURPOSE: This study is aimed to adapt a three-dimensional (3-D) in vitro angiogenesis model to the ophthalmology field using retinal endothelial cells (REC). This system is applied to assess the angiogenic capacity of aqueous humor (AH) from patients with ocular disorders, and to test the effect of VEGF inhibitor (aflibercept) on induced angiogenesis. METHODS: Human REC and umbilical vein endothelial cells (HUVEC) and pericytes were co-cultured in a gel matrix with 25-200 ng/ml pro-angiogenic growth factors (GF)...
May 10, 2018: Eye
https://www.readbyqxmd.com/read/29739007/optical-coherence-tomography-angiography-to-quantify-choroidal-neovascularization-in-response-to-aflibercept
#8
Jun Takeuchi, Keiko Kataoka, Yasuki Ito, Kei Takayama, Tetsuhiro Yasuma, Hiroki Kaneko, Hiroko Terasaki
PURPOSE: To investigate the microvascular changes in choroidal<X00_Del_Blind>0</X00_Del_Blind> neovascularization (CNV) using optical coherence tomography angiography (OCTA) during anti-vascular endothelial growth factor (VEGF) therapies. METHODS: We retrospectively collected data on consecutive treatment-naïve eyes with typical age-related macular degeneration that initially received 3 aflibercept injections. OCTA was performed at baseline and at 1, 2, and 4 months of follow-up...
May 8, 2018: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/29735320/intravitreal-aflibercept-therapy-in-eyes-with-chronic-central-serous-chorioretihopathy-short-term-results
#9
K Tekin, P Cakar Ozdal, B Gulpamuk, M Yasin Teke
OBJECTIVES: To evaluate the short term efficacy and tolerability results of intravitreal aflibercept injection as a treatment option for eyes with chronic central serous chorioretinopathy (CSCR). MATERIAL AND METHODS: A prospective longitudinal study. Ten eyes of 10 patients with chronic CSCR who had been followed for >6months after the first intravitreal injection of aflibercept were recruited for the study. The best corrected visual acuity (BCVA) and central macular thickness (CMT) values obtained by spectral-domain optical coherence tomography were recorded at baseline and the first, third, and sixth months after the injection...
May 4, 2018: Archivos de la Sociedad Española de Oftalmología
https://www.readbyqxmd.com/read/29715501/pharmacology-study-of-a-chimeric-decoy-receptor-trap-fusion-protein-on-retina-neovascularization-by-dual-blockage-of-vegf-and-fgf-2
#10
Jing Jiang, Ke Xu, Ling Wang, Wei Xin, Guorui Zhao, Min Huang, Shenjun Li, Xuejing Luan, Jianmin Fang
BACKGROUND: Clinical anti-vascular epithelial growth factor (VEGF) therapy trials faced a major challenge due to upregulated expression of other pro-angiogenic factors, such as fibroblast growth factor-2 (FGF-2). RC28, a novel recombinant dual decoy receptor IgG1 Fc-fusion protein, can block VEGFA and FGF-2 simultaneously. It is designed for the treatment of neovascular age-related macular degeneration and other pathological ocular neovascularization. The present study investigated the prevention efficacy of RC28 on choroidal neovascularization (CNV) in a monkey model and compared to the other mono VEGF antagonists; biodistribution and pharmacokinetics performance were also investigated...
April 28, 2018: European Journal of Pharmaceutical Sciences
https://www.readbyqxmd.com/read/29713139/foveal-threshold-and-photoreceptor-integrity-for-prediction-of-visual-acuity-after-intravitreal-aflibercept-on-age-related-macular-degeneration
#11
Tsutomu Sakai, Sachiyo Okude, Hiroshi Tsuneoka
Purpose: To determine whether baseline foveal threshold and photoreceptor integrity can predict best-corrected visual acuity (BCVA) at 12 months after intravitreal aflibercept (IVA) therapy in eyes with neovascular age-related macular degeneration (AMD). Patients and methods: We evaluated 25 eyes of 25 patients with treatment-naïve neovascular AMD who received IVA once a month for 3 months, followed by once every 2 months for 8 months. BCVA, integrity of the external limiting membrane (ELM) or the ellipsoid zone (EZ) of the photoreceptors, and retinal sensitivity were determined before (baseline) and at 6 and 12 months after initial IVA...
2018: Clinical Ophthalmology
https://www.readbyqxmd.com/read/29710026/-embolic-stroke-immediately-after-initial-administration-of-intravitreal-aflibercept
#12
Hironori Mizutani, Yuichiro Inatomi, Takaomi Singu, Makoto Nakajima, Toshiro Yonehara, Yukio Ando
A 72-year-old man was admitted to our hospital because of right upper limb monoplegia 8 hours after the initial intravitreal injection of aflibercept, which is an inhibitor of vascular endothelial growth factor. Magnetic resonance diffusion-weighted images showed recent ischemic lesions in the left corona radiata and the right superior frontal gyrus. Laboratory findings showed mild hyperfibrinolysis. A patent foramen ovale was diagnosed on transesophageal echocardiography; however, lower-extremity ultrasonography did not detect deep vein thrombosis...
April 28, 2018: Rinshō Shinkeigaku, Clinical Neurology
https://www.readbyqxmd.com/read/29700575/comparison-of-tumor-size-assessments-in-tumor-growth-inhibition-overall-survival-models-with-second-line-colorectal-cancer-data-from-the-velour-study
#13
Laurent Claret, Christina Pentafragka, Sanja Karovic, Binsheng Zhao, Lawrence H Schwartz, Michael L Maitland, Rene Bruno
PURPOSE: To compare lesion-level and volumetric measures of tumor burden with sum of the longest dimensions (SLD) of target lesions on overall survival (OS) predictions using time-to-growth (TTG) as predictor. METHODS: Tumor burden and OS data from a phase 3 randomized study of second-line FOLFIRI ± aflibercept in metastatic colorectal cancer were available for 918 patients out of 1216 treated (75%). A TGI model that estimates TTG was fit to the longitudinal tumor size data (nonlinear mixed effect modeling) to estimate TTG with: SLD, sum of the measured lesion volumes (SV), individual lesion diameters (ILD), or individual lesion volumes (ILV)...
April 26, 2018: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/29682574/baseline-predictors-of-visual-acuity-outcome-in-patients-with-wet-age-related-macular-degeneration
#14
REVIEW
Xinyuan Zhang, Timothy Y Y Lai
Age-related macular degeneration (AMD) is one of the leading causes of severe vision loss in people over 60 years. Wet AMD (wAMD) causes more severe visual acuity (VA) loss compared with the dry form due to formation of choroidal neovascularization (CNV). Antivascular endothelial growth factor (anti-VEGF) agents such as ranibizumab and aflibercept are now the standard of care treatment for wAMD. Unfortunately, up to a quarter of anti-VEGF-treated wAMD patients might not fully benefit from intravitreal injections and CNV activity may not respond to the treatment and these patients are called anti-VEGF nonresponders...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29681832/one-year-outcome-of-aflibercept-and-photodynamic-therapy-in-a-caucasian-patient-with-polypoidal-choroidal-vasculopathy-refractory-to-ranibizumab-and-photodynamic-therapy
#15
Marta Medina-Baena, María Jesús Huertos-Carrillo, Laura Rodríguez, Juan Ignacio García-Pulido, Carlos Cornejo-Castillo, José María Calandria-Amiguetti
Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular age-related macular degeneration characterised by an abnormal branching vascular network with aneurysmal polypoidal choroidal vascular lesions. PCV is more prevalent in Asian populations than in Caucasians, which may explain its underdiagnosis in Western countries. Evidence regarding the efficacy of different anti-vascular endothelial growth factor (anti-VEGF) agents on PCV is scarce, with most of these studies being conducted in Asian treatment-naïve patients...
January 2018: Case Reports in Ophthalmology
https://www.readbyqxmd.com/read/29677368/in-vivo-characterization-of-spontaneous-retinal-neovascularization-in-the-mouse-eye-by-multifunctional-optical-coherence-tomography
#16
Marco Augustin, Matthias Wechdorn, Ulrike Pfeiffenberger, Tanja Himmel, Stanislava Fialová, René M Werkmeister, Christoph K Hitzenberger, Martin Glösmann, Bernhard Baumann
Purpose: To investigate the early development of spontaneous retinal neovascularization in the murine retina by a multifunctional optical coherence tomography approach. To characterize involved tissue changes in vivo and describe structural and functional changes over time. Methods: A multifunctional optical coherence tomography (OCT) system providing 3-fold contrast comprising reflectivity, polarization sensitivity, and OCT angiography (OCTA) was utilized to image very-low-density lipoprotein receptor (VLDLR) knockout mice...
April 1, 2018: Investigative Ophthalmology & Visual Science
https://www.readbyqxmd.com/read/29672933/anti-angiogenic-efficacy-of-aflibercept-and-bevacizumab-in-primary-oral-squamous-cell-carcinoma-cells
#17
Meysam Ganjibakhsh, Roshanak Monshizadeh, Ahmad Nasimian, Pouyan Aminishakib, Parvaneh Farzaneh, Sahar Tavakoli Shiraji, Ata Garajei, Sedigheh Rahrotaban, Fereshteh Baghaei, Neda Sadat Gohari
BACKGROUND: In recent decades, anti-angiogenic treatment strategy has been well-described in cancer treatment. The anti-angiogenic activity of both Bevacizumab and Aflibercept have been researched on ten previously established primary Oral Squamous Cell Carcinoma (OSCC) cells of an Iranian population with different levels of purity, in an attempt to find the most effective anti-angiogenic targeted drug. METHODS: To investigate and compare the effect of Bevacizumab and Aflibercept on Vascular Endothelial Growth Factor (VEGF) secretion of ten primary OSCC cells, cell proliferation and viability were assessed by ELISA and MTT assays...
April 19, 2018: Journal of Oral Pathology & Medicine
https://www.readbyqxmd.com/read/29670046/resistance-to-anti-angiogenic-therapy-in-cancer-alterations-to-anti-vegf-pathway
#18
REVIEW
Yoshiro Itatani, Kenji Kawada, Takamasa Yamamoto, Yoshiharu Sakai
Anti-angiogenic therapy is one of the promising strategies for many types of solid cancers. Bevacizumab (Avastin), a recombinant humanized monoclonal antibody of vascular endothelial growth factor (VEGF) A, was approved for the first time as an anti-angiogenic drug for the treatment of metastatic colorectal cancer (CRC) by the Food and Drug Administration (FDA) in 2004. In addition, the other VEGF pathway inhibitors including small molecule tyrosine kinase inhibitors (sunitinib, sorafenib, and pazopanib), a soluble VEGF decoy receptor (aflibercept), and a humanized monoclonal antibody of VEGF receptor 2 (VEGFR2) (ramucirumab) have been approved for cancer therapy...
April 18, 2018: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29664981/intravitreal-ziv-aflibercept-for-diabetic-macular-edema-48-week-outcomes
#19
Gabriel Costa de Andrade, João Rafael de Oliveira Dias, André Maia, Michel Eid Farah, Carsten H Meyer, Eduardo Buchele Rodrigues
BACKGROUND AND OBJECTIVE: To study the safety and efficacy of intravitreal injections of ziv-aflibercept (IVI-ZA) (Zaltrap; Sanofi-Aventis and Regeneron Pharmaceuticals, Tarrytown, NY) during a period of 48 weeks in patients with diabetic macular edema (DME). PATIENTS AND METHODS: Seven consecutive patients with DME were enrolled and submitted to 12 consecutive IVI-ZA with a 4-week interval. The safety parameters included changes in full-field electroretinogram (ERG) and systemic or ocular complications, and the efficacy parameters were the mean change from baseline in best-corrected visual acuity (BCVA) and central retinal thickness (CRT)...
April 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29662298/anti-vegf-treatment-of-macular-edema-associated-with-retinal-vein-occlusion-patterns-of-use-and-effectiveness-in-clinical-practice-echo-study-report-2
#20
J Michael Jumper, Pravin U Dugel, Sanford Chen, Kevin J Blinder, John G Walt
Purpose: To evaluate the efficacy, safety, and injection frequency of vascular endothelial growth factor (VEGF) antagonists in the treatment of macular edema secondary to retinal vein occlusion (RVO) in clinical practice. Patients and methods: A multicenter retrospective study of the medical records of 165 patients (95 branch RVO, 70 central RVO) treated with at least three anti-VEGF injections in the study eye was conducted. Available data collected for at least 6 months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF injections, other treatments/procedures for RVO, and adverse events...
2018: Clinical Ophthalmology
keyword
keyword
1772
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"